Allarity Therapeutics announced that two patients in its Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have surpassed one year of treatment. These patients were pre-screened using Allarity's Drug Response Predictor (DRP®) companion diagnostic, which identified them as likely responders to the dual PARP/Tankyrase inhibitor treatment.The trial, conducted at multiple sites in the US and UK, implements a revised protocol with twice-daily dosing of stenoparib (200mg morning, 400mg evening). The enrolled patients, who had previously undergone multiple treatments including platinum, taxanes, and PARP inhibitors, demonstrated sustained clinical benefit with confirmed complete response and long-term disease stability.CEO Thomas Jensen emphasized the significance of extending life by 52 weeks in heavily pre-treated patients. The company is actively planning to accelerate stenoparib's path toward regulatory approval, with additional program updates expected in the coming months.

Allarity Therapeutics announced that two patients in its Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have surpassed one year of treatment. These patients were pre-screened using Allarity's Drug Response Predictor (DRP®) companion diagnostic, which identified them as likely responders to the dual PARP/Tankyrase inhibitor treatment.The trial, conducted at multiple sites in the US and UK, implements a revised protocol with twice-daily dosing of stenoparib (200mg morning, 400mg evening). The enrolled patients, who had previously undergone multiple treatments including platinum, taxanes, and PARP inhibitors, demonstrated sustained clinical benefit with confirmed complete response and long-term disease stability.CEO Thomas Jensen emphasized the significance of extending life by 52 weeks in heavily pre-treated patients. The company is actively planning to accelerate stenoparib's path toward regulatory approval, with additional program updates expected in the coming months.